AARD EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026

Faruqi & Faruqi is investigating potential securities-law claims against Aardvark Therapeutics (NASDAQ: AARD) and reminded investors of an October 13, 2026 deadline to seek lead-plaintiff status in a federal class action. The action covers Aardvark common stock traceable to its February 13, 2025 IPO and securities purchased between February 13, 2025 and May 14, 2026. The notice creates litigation and potential liability risk for the company, although no specific allegations or damages were detailed.

Analysis

This is primarily an incremental overhang rather than a new fundamental datapoint: plaintiff-firm notices are often solicitation-driven and do not independently establish liability or damages. For AARD, the near-term effect is likely higher retail-holder selling and reduced willingness of new specialist capital to underwrite the name while disclosure risk is unresolved; liquidity is the key transmission mechanism, particularly if average daily dollar volume is low.

Over the next 1-3 months, the material catalyst is not the lead-plaintiff deadline but any underlying complaint, amended filing, or company response that specifies alleged omissions and ties them to a clinical, regulatory, commercialization, or financing event. A securities suit can raise D&O expense and management distraction, but it generally does not impair enterprise value unless it reveals an unmodeled setback or constrains access to equity financing. For a development-stage biotech, a lower share price can become self-reinforcing if cash runway is short, because the probability and dilution of a follow-on increase.

The contrarian case is that the market may already view the notice as boilerplate. If AARD has cash sufficient through its next value-inflection readout and no new adverse operating disclosure emerges, litigation-related weakness could be temporary; settlement values are frequently immaterial relative to biotech valuation swings. The thesis is falsified by evidence that the alleged conduct concerns data integrity, regulatory correspondence, or a previously undisclosed cash-runway shortfall rather than ordinary post-IPO price volatility.

Key Decisions for Investors

• Do not initiate a directional position solely on this notice; treat the October 13 lead-plaintiff date as an event-risk alert, not a fundamental catalyst.
• For existing AARD longs, reduce exposure or hedge into the next financing-sensitive window if cash runway is under 12 months; reassess after the complaint allegations and the company’s response are available. A disclosed financing need or guidance/cash-runway reduction would warrant a further de-risking.
• For short exposure, wait for independently verifiable allegations involving clinical data, FDA interactions, or undisclosed dilution. A short based only on litigation headlines has poor risk/reward in a potentially thin, high-beta biotech and is vulnerable to technical rebounds.
• Monitor AARD’s cash balance, quarterly operating cash burn, ATM/follow-on capacity, and short interest. A cash runway extending beyond the next major clinical or regulatory catalyst would weaken the bearish financing-feedback thesis; a sub-12-month runway strengthens it.